New hope for MS patients: modified drug regimen under trial

NCT ID NCT05877963

Recruiting now Disease control Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times

Summary

This study tests a modified dosing schedule of ublituximab, a drug that targets certain immune cells, in 800 people with relapsing multiple sclerosis (MS). The goal is to see if the new regimen reduces brain lesions better than current approaches. Participants include those new to treatment or switching from other therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

TG Investigational Site
RECRUITING

Fort Collins, Colorado, 80528, United States
TG Investigational Site
RECRUITING

Farmington, Michigan, 48334, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Birmingham, Alabama, 35209, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Cullman, Alabama, 35058, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Orange, California, 92697, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Washington D.C., District of Columbia, 20007, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Tampa, Florida, 33612, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Chicago, Illinois, 60612, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Indianapolis, Indiana, 46256, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Iowa City, Iowa, 52242, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Overland Park, Kansas, 66212, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Lutherville, Maryland, 21093, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Boston, Massachusetts, 00002, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Foxborough, Massachusetts, 02035, United States
TG Therapeutics Investigational Trial Site
RECRUITING

North Worcester, Massachusetts, 01655, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Wellesley, Massachusetts, 02481uni, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Golden Valley, Minnesota, 55422, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Plymouth, Minnesota, 55446, United States
TG Therapeutics Investigational Trial Site
RECRUITING

St Louis, Missouri, 63131, United States
TG Therapeutics Investigational Trial Site
RECRUITING

New York, New York, 10025, United States
TG Therapeutics Investigational Trial Site
RECRUITING

New York, New York, 11021, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Raleigh, North Carolina, 27607, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Cleveland, Ohio, 44195, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Dayton, Ohio, 45417, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Greenville, South Carolina, 29605, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Knoxville, Tennessee, 37922, United States
TG Therapeutics Investigational Trial Site
ACTIVE_NOT_RECRUITING

Houston, Texas, 77030, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Salt Lake City, Utah, 84103, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Vienna, Virginia, 22182, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Kirkland, Washington, 98034, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Seattle, Washington, 98109, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Spokane, Washington, 99208, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Milwaukee, Wisconsin, 53226, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Bydgoszcz, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Katowice, 40-555, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Katowice, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Kielce, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Krakow, 31-826, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Lodz, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Olsztyn, 10-561, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Poznan, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Warsaw, 04-141, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Zabrze, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Żory, 44-240, Poland
TG Therapeutics Investigational Trial SiteCharlotte
RECRUITING

Charlotte, North Carolina, 28204, United States

Conditions

Explore the condition pages connected to this study.

RELAPSING MULTIPLE SCLEROSIS